Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:9373251rdf:typepubmed:Citationlld:pubmed
pubmed-article:9373251lifeskim:mentionsumls-concept:C0083031lld:lifeskim
pubmed-article:9373251lifeskim:mentionsumls-concept:C0597357lld:lifeskim
pubmed-article:9373251lifeskim:mentionsumls-concept:C1749467lld:lifeskim
pubmed-article:9373251lifeskim:mentionsumls-concept:C1414557lld:lifeskim
pubmed-article:9373251lifeskim:mentionsumls-concept:C0231491lld:lifeskim
pubmed-article:9373251lifeskim:mentionsumls-concept:C1551336lld:lifeskim
pubmed-article:9373251pubmed:issue11lld:pubmed
pubmed-article:9373251pubmed:dateCreated1997-12-23lld:pubmed
pubmed-article:9373251pubmed:abstractTextWe have expressed a soluble N-glycosylated form of the murine interleukin-11 (IL-11) receptor alpha-chain (sIL-11R) and examined signaling in cells expressing the gp130 molecule. In the presence of gp130 but not the transmembrane IL-11R, the sIL-11R mediated IL-11-dependent differentiation of M1 leukemic cells and proliferation in Ba/F3 cells. Early intracellular events stimulated by the sIL-11R including phosphorylation of gp130, STAT 3, and SHP-2 were similar to signaling through the transmembrane IL-11R. IL-11 bound to sIL-11R with low affinity (kd 10 to 50 nmol/L). Binding of sIL-11R to gp130 was IL-11 dependent with intermediate affinity (kd 1.5 to 3.0 nmol/L). However, the concentration of IL-11 required for signaling through the sIL-11R was 10- to 20-fold greater than that required for cells expressing the transmembrane IL-11R and gp130 in the absence of sIL-11R. Furthermore, the sIL-11R was capable of antagonizing the activity of IL-11 when tested on cells expressing the transmembrane IL-11R and gp130. We propose that the observed IL-11 antagonism by the sIL-11R may depend on limiting numbers of gp130 molecules on cells already expressing the transmembrane IL-11R.lld:pubmed
pubmed-article:9373251pubmed:languageenglld:pubmed
pubmed-article:9373251pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9373251pubmed:citationSubsetAIMlld:pubmed
pubmed-article:9373251pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9373251pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9373251pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9373251pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9373251pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9373251pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9373251pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9373251pubmed:statusMEDLINElld:pubmed
pubmed-article:9373251pubmed:monthDeclld:pubmed
pubmed-article:9373251pubmed:issn0006-4971lld:pubmed
pubmed-article:9373251pubmed:authorpubmed-author:MurrayLLlld:pubmed
pubmed-article:9373251pubmed:authorpubmed-author:CurtinD EDElld:pubmed
pubmed-article:9373251pubmed:authorpubmed-author:RobertsBBlld:pubmed
pubmed-article:9373251pubmed:authorpubmed-author:NicolaNNlld:pubmed
pubmed-article:9373251pubmed:authorpubmed-author:BegleyC GCGlld:pubmed
pubmed-article:9373251pubmed:authorpubmed-author:HiltonD JDJlld:pubmed
pubmed-article:9373251pubmed:issnTypePrintlld:pubmed
pubmed-article:9373251pubmed:day1lld:pubmed
pubmed-article:9373251pubmed:volume90lld:pubmed
pubmed-article:9373251pubmed:ownerNLMlld:pubmed
pubmed-article:9373251pubmed:authorsCompleteYlld:pubmed
pubmed-article:9373251pubmed:pagination4403-12lld:pubmed
pubmed-article:9373251pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:9373251pubmed:meshHeadingpubmed-meshheading:9373251-...lld:pubmed
pubmed-article:9373251pubmed:meshHeadingpubmed-meshheading:9373251-...lld:pubmed
pubmed-article:9373251pubmed:meshHeadingpubmed-meshheading:9373251-...lld:pubmed
pubmed-article:9373251pubmed:meshHeadingpubmed-meshheading:9373251-...lld:pubmed
pubmed-article:9373251pubmed:meshHeadingpubmed-meshheading:9373251-...lld:pubmed
pubmed-article:9373251pubmed:meshHeadingpubmed-meshheading:9373251-...lld:pubmed
pubmed-article:9373251pubmed:meshHeadingpubmed-meshheading:9373251-...lld:pubmed
pubmed-article:9373251pubmed:meshHeadingpubmed-meshheading:9373251-...lld:pubmed
pubmed-article:9373251pubmed:meshHeadingpubmed-meshheading:9373251-...lld:pubmed
pubmed-article:9373251pubmed:meshHeadingpubmed-meshheading:9373251-...lld:pubmed
pubmed-article:9373251pubmed:meshHeadingpubmed-meshheading:9373251-...lld:pubmed
pubmed-article:9373251pubmed:meshHeadingpubmed-meshheading:9373251-...lld:pubmed
pubmed-article:9373251pubmed:meshHeadingpubmed-meshheading:9373251-...lld:pubmed
pubmed-article:9373251pubmed:meshHeadingpubmed-meshheading:9373251-...lld:pubmed
pubmed-article:9373251pubmed:meshHeadingpubmed-meshheading:9373251-...lld:pubmed
pubmed-article:9373251pubmed:year1997lld:pubmed
pubmed-article:9373251pubmed:articleTitleRecombinant soluble interleukin-11 (IL-11) receptor alpha-chain can act as an IL-11 antagonist.lld:pubmed
pubmed-article:9373251pubmed:affiliationWalter and Eliza Hall Institute of Medical Research, Victoria, Australia.lld:pubmed
pubmed-article:9373251pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:9373251pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
entrez-gene:16157entrezgene:pubmedpubmed-article:9373251lld:entrezgene
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9373251lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9373251lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9373251lld:pubmed